CLEC2D Antibody

Code CSB-PA114834
Size US$166
Order now
Image
  • The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA114834(CLEC2D Antibody) at dilution 1/60, on the right is treated with fusion protein. (Original magnification: ×200)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
C type lectin related f antibody; C type lectin superfamily 2; member D antibody; C-type lectin domain family 2 member D antibody; CLAX antibody; CLC2D_HUMAN antibody; CLEC2D antibody; CLEC2D protein antibody; Clec2d5 antibody; L LT1 antibody; Lectin like NK cell receptor antibody; Lectin like transcript 1 antibody; Lectin-like NK cell receptor antibody; Lectin-like transcript 1 antibody; LLT-1 antibody; LLT1 antibody; OCIL antibody; Osteoclast inhibitory lectin antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Fusion protein of Human CLEC2D
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:1000-1:5000
IHC 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis. Inhibits osteoclast formation. Inhibits bone resorption. Modulates the release of interferon-gamma. Binds high molecular weight sulfated glycosaminoglycans.
Gene References into Functions
  1. These results show that susceptibility of normal articular chondrocytes to lysis by NK cells is modulated by NKR-P1A/LLT1 interactions. Thus, NKR-P1A/LLT1 interaction might provide some novel target for therapeutic interventions in the course of pathological cartilage injury. PMID: 29212911
  2. Blocking LLT1-NKRP1A interaction will make prostate cancer cells susceptible to killing by NK cells, suggesting a therapeutic option for treatment of prostate cancer. PMID: 27626681
  3. these data suggest that LLT1-CD161 interactions play a novel and important role in B cell maturation within the Germinal center in humans. PMID: 26829983
  4. In RA joints, LLT1 is expressed by cells of the monocyte/macrophage lineage. PMID: 26147876
  5. The hexamer of glycosylated LLT1 consists of three classical dimers. The hexameric packing may indicate a possible mode of interaction of C-type lectin-like proteins in the glycosylated form. PMID: 25760607
  6. One polymorphism in LLT1 was found to be associated with our Crohn's Disease population (P<0.034).Our Ulcerative Colitis cohort was not associated with the variation in LLT1 (P=0.33) PMID: 22664939
  7. LLT1 and CD161 have roles in modulating immune responses to pathogens; and interferon-gamma contributes to modulate immune responses PMID: 21930700
  8. Molecular basis for LLT1 protein recognition by human CD161 protein (NKRP1A/KLRB1). PMID: 21572041
  9. Data show that only CLEC2D isoform 1 (LLT1) is expressed on the cell surface. PMID: 20843815
  10. LLT1 used Src-PTK, p38 and ERK signalling pathways, but not PKC, PI3K or calcineurin pathways, to increase production of IFN-gamma by human natural killer cells. PMID: 20415786
  11. LLT1 induces Interferon Type II production by natural killer cells. PMID: 15104121
  12. Data show that osteoclast inhibitory lectin (OCIL) binds a range of physiologically important glycosaminoglycans, and this property may modulate OCIL actions upon other cells [OCIL]. PMID: 15123656
  13. Engagement of CD161 on NK cells with LLT1 expressed on target cells inhibited NK cell-mediated cytotoxicity and IFN-gamma secretion. LLT1/CD161 interaction in the presence of a TCR signal enhanced IFN-gamma production by T cells PMID: 16339512
  14. LLT1 on target cells can inhibit NK cytotoxicity via interactions with CD161. LLT1 activates NFAT-GFP reporter cells expressing a CD3zeta-CD161 chimeric receptor; reciprocally, reporter cells with a CD3zeta-LLT1 chimeric receptor are stimulated by CD161 PMID: 16339513
  15. Expression of LLT1 on activated dendritic cells and B cells suggests that it might regulate the cross-talk between NK cells and APCs PMID: 18453569
  16. Women with a lysine (GG genotype) at position 19 of the OCIL protein displayed lower bone mineral density at femoral neck and at lumbar spine sites than women having an asparagine residue. PMID: 18465072

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type II membrane protein.; [Isoform 2]: Endoplasmic reticulum.; [Isoform 4]: Endoplasmic reticulum.
Tissue Specificity
Detected in peripheral blood leukocytes, osteoblasts, lymph node, thymus and spleen. Isoform 1, isoform 2 and isoform 4 are expressed in T- and B-lymphocytes, and at lower levels in NK cells. They are also expressed in B-cell lines and LPS-matured monocyt
Database Links

HGNC: 14351

OMIM: 605659

KEGG: hsa:29121

UniGene: Hs.268326

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*